ATTORNEY DOCKET NO. PG4442	
Form PTO-1595	U.S. DEPARTMENT OF COMMERCE
Patent and Trademark Office	
RECORDATION FORM COVER SHEET PATENTS ONLY	
CERTIFICATION OF FACSIMILE TRANSMISSION	
	alle transmitted to the Patent and Trademark Office Assignment
Branch at (703) 306-5995 on <u>May 7, 2003</u> by	
Admin's name here: Elaine Martens	
sim: Elsere Marters	
Sign: Clane / Marlens	
Commissioner of Patents. Please record the attached original documents or copy thereof.	
1. Name of conveying party(ics)	2. Name and address of receiving party(ies)
	ON WWWALINE DEPOSITAN CORDORATION
Keith BIGGADIKE	SMITHKLINE BEECHAM CORPORATION One Franklin Plaza
	PO BOX 7929
Paul JONES	Philadelphia, Pennsylvania 19101-7929
Jeremy John PAYNE	US
	Additional name(s) and addresses attached?0
Additional names of conveying party(ies) attached?	[] yes [X] no
[] yes [X] no	
3. Description of the interest conveyed:	J
[X] Assignment, please record and return	[] Merger
[] Security Agreement	[] Change of Name
[] Other	
Execution date of Assignment: August 14, 2001, August 14, 2001 and August 14, 2001	
4. Application number(s) or patent number(s). Additional Sheets attached? Yes X No	
A. Patent Application No.(s)	B. Patent No.(s)
10/343,842 filed February 04, 2003	
-	ith a new conflication, the execution date of the conflication is
If this document is being filed together with a new application, the execution date of the application is	
5. Name and address of party to whom	6. Total number of applications and patents involved 1.
correspondence concerning documents should	
be mailed:	7. Total Fee (37 C.F.R. 3.41) \$40.00
6.	
David J. Levy	8. Please charge this fee to deposit account No. $07-1392$.
GlaxoSmithKline Corporate Intellectual Property MAL P475	
Corporate Intellectual Property-MAI-B475 Five Moore Drive	The Commissioner is hereby authorized to charge any additional fees
P.O. Box 13398	under 37 CFR 1.16 or 1.17 which may be required by this paper, or
Research Triangle Park, NC 27709-3398	credit any overpayment, to our Deposit Account No. <u>07-1392</u> .
_	
DO NOT USE THIS SPACE	
9. Statement and Signature.	
To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the original document.	
Charles E. DADSWELL (Reg. 35,851 Name of Person Signing Signature Signature May 7, 2003	
Total number of pages including cover sheet, attachments and document: 4	

PATENT REEL: 013632 FRAME: 0289

ASSIGNMENT

WHEREAS I/WE, Keith BIGGADIKE, Paul JONES and Jeremy John PAYNE all of GlaxoSmithKline, Gunnels Wood Road, Stevenage, Hertfordshire, SG1 2NY, GB (hereinafter called "the inventor(s)") have invented or discovered "Novel Anti-Inflammatory Androstane Derivatives" (hereinafter called "the invention") for which a patent application No. 0019172.6 was filed on 5th August 2000 in the United Kingdom and patent application No. 0108800.4 was filed on 7th April 2001 in the United Kingdom and for which an international patent application is now being filed designating the United States of America. I/we hereby authorize and request that the filing date and PCT International application, when known, be inserted here in parentheses;

(PCT /GB01/03499 filed August 3, 2001

WHEREAS the invention, being made in the circumstances set out in Section 39(1)(a) of the United Kingdom Patents Act 1977, belongs to my/our employer, namely GLAXO WELLCOME plc, a company incorporated in England whose registered address is Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex UB6 ONN, and

WHEREAS GLAXO RESEARCH AND DEVELOPMENT LIMITED, a company incorporated in England whose registered address is Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex UB6 ONN, England, is desirous of acquiring from GLAXO WELLCOME plc the whole right, title and interest in and to the invention and the application, and

WHEREAS GLAXO WELLCOME plc and GLAXO RESEARCH AND DEVELOPMENT LIMITED have authorised and requested my/our making the application, and

WHEREAS SMITHKLINE BEECHAM CORPORATION a corporation organised and existing under and by virtue of the laws of the State of Pennsylvania and having its principal place of business at One Franklin Plaza, P O Box 7929, Philadelphia, Pennsylvania 19101-7929, USA is desirous of acquiring from GLAXO RESEARCH AND DEVELOPMENT LIMITED the whole right, title and interest in and to the invention and the application in respect of the United States of America;

> PATENT REEL: 013632 FRAME: 0290

1

NOW, THEREFORE, to all whom it may concern be it known that I/we, the inventor(s), hereby confirm the ownership by GLAXO WELLCOME plc of the invention and the application by operation of law under the United Kingdom Patents Act 1977 and, if under the law of the United States of America l/we the inventor(s) have any ownership right, title and interest in the invention and the application (which I/we do not believe to be the case and claim no ownership right, title or interest in the invention and the application based on the law of the United Kingdom), I/we the inventor(s) nevertheless hereby assign and transfer such ownership right, title and interest in and to the invention and the application to GLAXO WELLCOME plc. GLAXO WELLCOME plc in turn hereby assigns and transfers to GLAXO RESEARCH AND DEVELOPMENT LIMITED its whole right, title and interest in and to the invention and the application. GLAXO RESEARCH AND DEVELOPMENT LIMITED in turn hereby assigns and transfers to SMITHKLINE BEECHAM CORPORATION its whole right, title and interest in and throughout the United States of America in and to the invention and the application and in and to any priority rights in respect of the invention and the application and in and to any divisional application, continuation or continuation in part application thereof, and in and to any extension or re-issue thereof, and I/we the inventor(s) and GLAXO WELLCOME plc and GLAXO RESEARCH AND DEVELOPMENT LIMITED hereby authorise and request any patent arising therefrom in the United States of America be issued to SMITHKLINE BEECHAM CORPORATION.

AND GLAXO WELLCOME plc and GLAXO RESEARCH AND DEVELOPMENT LIMITED hereby, and I/we the inventor(s) for myself/ourselves and my/our respective executors and legal representatives hereby, agree to provide information and make execute and deliver any and all other instruments in writing, and any and all further acts, applications, papers, affidavits, assignments and other documents which may be possible and are necessary or desirable to more effectually secure to and vest in SMITHKLINE BEECHAM CORPORATION, its successors and assigns, the whole right, title and interest in and to the invention and the application hereby assigned and transferred in respect of the United States of America.

IT is hereby declared that each of the transactions hereby effected does not form part of a larger transaction or of a series of transactions in respect of which the amount or value, or the aggregate amount or value, of the consideration exceeds £60,000.

PATENT REEL: 013632 FRAME: 0291

2

RECORDED: 05/07/2003

IN WITNESS whereof and with effect from 5th August 2000 the inventor(s) and Peter John GIDDINGS as Attorney of both GLAXO WELLCOME plc and GLAXO RESEARCH AND DEVELOPMENT LIMITED by virtue of Powers of Attorney granted by GLAXO WELLCOME plc and GLAXO RESEARCH AND DEVELOPMENT LIMITED respectively have hereunto set their respective hands.

SIGNED by Keith BIGGADIKE :

K. Beggadike

in the presence of:

Wever

SIGNED by Paul JONES:

1. Ame In the presence of:

Mover

SIGNED by Jeremy John PAYNE:

In the presence of:

Weller

SIGNED by Peter John GIDDINGS as the Attorney of each of Glaxo Wellcome plc and Glaxo Research and Development Limited:

Date: 04/09/01

3

PATENT

Date: 14th August 2001

Date: (4. Ancist. 2001

Date: 14 August 2001

NO. 8641 P. 4 PG4442/US